SUMO2 and prostate carcinoma: Additionally, double gene molecular subtype analysis with SUMO1, SUMO2, and XPO1 genes revealed survival outcome differences across molecular subtypes, further emphasizing NOP58’s critical role in prostate cancer biology and patient prognosis (Figures A1–C5).